Quarterly ResultAug 6, 2026, 07:25 AM
Sionna Therapeutics Q2 Net Loss $29.9M; Cash $268.3M, Funds Ops into 2028
AI Summary
Sionna Therapeutics reported a net loss of $29.9 million for the second quarter ended June 30, 2026, an increase from $18.1 million in the same period last year, driven by higher R&D and G&A expenses. The company maintained a strong cash position with $268.3 million in cash and equivalents, projected to fund operations into 2028. Operationally, Sionna confirmed that its PreciSION CF Phase 2a trial for SION-719 and Phase 1 dual combination trial for SION-451 are both on track to deliver topline data this summer.
Key Highlights
- Net loss for Q2 2026 was $29.9 million, compared to $18.1 million in Q2 2025.
- Research and development expenses increased to $21.9 million in Q2 2026.
- General and administrative expenses rose to $10.6 million in Q2 2026.
- Cash, cash equivalents, and marketable securities totaled $268.3 million as of June 30, 2026.
- Current cash position is expected to fund operations into 2028.
- PreciSION CF Phase 2a trial for SION-719 is on track for topline data this summer.
- Phase 1 dual combination trial for SION-451 is on track for topline data this summer.
Price Impact
More from SION